---
title: "Inhibikase wins FDA orphan drug designation for IKT-001 in PAH"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293613509.md"
description: "Inhibikase Therapeutics received FDA orphan drug designation for IKT-001 to treat pulmonary arterial hypertension (PAH). IKT-001, a prodrug of imatinib, targets an estimated 50,000 U.S. patients. This designation may provide development incentives such as tax credits, fee waivers, and seven years of market exclusivity upon approval."
datetime: "2026-07-23T12:07:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293613509.md)
  - [en](https://longbridge.com/en/news/293613509.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293613509.md)
generator: "portal-rs"
---

# Inhibikase wins FDA orphan drug designation for IKT-001 in PAH

-   Inhibikase Therapeutics received FDA orphan drug designation for IKT-001 to treat pulmonary arterial hypertension. \* IKT-001 is a prodrug of imatinib; designation targets an estimated 50,000 U.S. patients with PAH. \* Status may support development incentives, including potential tax credits, fee waivers, and seven years of exclusivity upon approval. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibikase Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607230800PRIMZONEFULLFEED9766727) on July 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [IKT.US](https://longbridge.com/en/quote/IKT.US.md)

## Related News & Research

- [Inhibikase Therapeutics replaces auditor CohnReznick with Deloitte](https://longbridge.com/en/news/297083175.md)
- [Inhibikase raises $50M to fund PAH program](https://longbridge.com/en/news/292740299.md)
- [United Therapeutics says FDA accepts ralinepag NDA for pulmonary arterial hypertension](https://longbridge.com/en/news/296776376.md)
- [NKT qualifies 525 kV HVDC subsea power cable system for operation at 90 °C](https://longbridge.com/en/news/296745080.md)
- [SSE wins local approval for Cambushinnie 400kV substation near Braco](https://longbridge.com/en/news/296584916.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**